Table 1. Active clinical trials using immunotherapy in operable non-small cell lung cancer.

Identifier (ClinicalTrials.gov)	Sponsor	Stage	Phase	Immune therapy	Arms	Accrual	Endpoint	Status
NCT02572843	Swiss Group for Clinical Cancer Research	IIIA (N2)	II	Neoadjuvant and adjuvant durvalumab	Cisplatin/docetaxel ± neoadjuvant and adjuvant durvalumab	68	Event-free survival	Open
NCT02818920	Duke University	IB, II, IIIA	II	Neoadjuvant and adjuvant pembrolizumab	Single arm	32	Safety	Open, not yet recruiting
NCT02716038	Columbia University	IB–IIIA	II	Neoadjuvant atezolizumab	Single arm; combined with Nab-paclitaxel and carboplatin	30	Efficacy	Open
NCT02259621	Sidney Kimmel Cancer Center; Memorial Sloan Kettering Cancer Center	I–IIIA	II	Neoadjuvant nivolumab	Single arm	20	Safety	Open
NCT02595944	NCI-EA5142	IB–IIIA	III	Adjuvant nivolumab	Postoperative platinum-based chemotherapy as per standard of care, ± PORT ± nivolumab	718	DFS/OS	Open
NCT02273375	Canadian Cancer Trials Group	IB–IIIA	III	Adjuvant durvalumab	Postoperative platinum-based chemotherapy as per standard of care (no RT) ± durvalumab	1,100	Disease-free survival	Open

NCI, National Cancer Institute; RT, radiation therapy; DFS, disease-free survival; OS, overall survival; PORT, postoperative radiation therapy.